Merrimack Pharm (MACK) Posts Mixed Q1 Results

Merrimack Pharm (NASDAQ: MACK) reported Q1 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $13.03 million versus the consensus estimate of $11.93 million.

For earnings history and earnings-related data on Merrimack Pharm (MACK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15